Kuros, Aeris in lung volume reduction pact
This article was originally published in Clinica
Swiss biotechnology company Kuros Biosurgery has granted Aeris Therapeutics exclusive rights to its lung volume reduction patents. Kuros has allowed Woburn, Massachusetts-based Aeris, a specialist in emphysema and other lung diseases, access to certain patents that cover the delivery of certain drugs in a fibrin sealant. In return, Kuros, which is headquartered in Zurich, will receive an undisclosed upfront payment, milestones and royalties from sales of Aeris’ AeriSeal biologic lung volume reduction (BLVR) system. The non-surgical AeriSeal BLVR system is currently preparing for phase III clinical trials. According to Kuros, it is designed to deliver a proprietary mixture of drugs and biologics that form a bio-absorbable gel (which contains a fibrin sealant) to diseased areas of the lungs.